Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) FCF Margin (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed FCF Margin for 16 consecutive years, with 33.15% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin rose 3225.0% to 33.15% in Q4 2025 year-over-year; TTM through Dec 2025 was 9.33%, a 1113.0% increase, with the full-year FY2025 number at 9.33%, up 1127.0% from a year prior.
  • FCF Margin was 33.15% for Q4 2025 at Anika Therapeutics, up from 5.44% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 35.87% in Q4 2023 to a low of 191.25% in Q4 2022.
  • A 5-year average of 6.34% and a median of 1.71% in 2024 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: plummeted -21490bps in 2022, then surged 22712bps in 2023.
  • Anika Therapeutics' FCF Margin stood at 23.65% in 2021, then plummeted by -909bps to 191.25% in 2022, then surged by 119bps to 35.87% in 2023, then crashed by -97bps to 0.9% in 2024, then soared by 3589bps to 33.15% in 2025.
  • Per Business Quant, the three most recent readings for ANIK's FCF Margin are 33.15% (Q4 2025), 5.44% (Q3 2025), and 6.43% (Q2 2025).